Cargando…

Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities. In particular, the association between psoriasis and cardiometabolic comorbidities, including cardiovascular diseases (CVDs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Jiangluyi, Cui, Lian, Wang, Yu, Li, Ying, Zhang, Xilin, Shi, Yuling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600112/ https://www.ncbi.nlm.nih.gov/pubmed/34803716 http://dx.doi.org/10.3389/fphar.2021.774808

Ejemplares similares

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2020)

Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated
por: Kanda, Naoko
Publicado: (2021)

Xiao-Yin-Fang Therapy Alleviates Psoriasis-like Skin Inflammation Through Suppressing γδT17 Cell Polarization
por: Zhang, Xilin, et al.
Publicado: (2021)

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017)

Advances in the pathogenesis of psoriasis: from keratinocyte perspective
por: Zhou, Xue, et al.
Publicado: (2022)

RNA modifications: importance in immune cell biology and related diseases
por: Cui, Lian, et al.
Publicado: (2022)

Cardiometabolic risk in psoriasis: differential effects of biologic agents
por: Kaplan, Mariana J
Publicado: (2008)

Pathogenesis of Psoriasis: Focus on Autoinflammation
por: Marzano, Angelo Valerio, et al.
Publicado: (2018)

Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
por: Hagino, Teppei, et al.
Publicado: (2023)

Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study
por: Crutzen, Stijn, et al.
Publicado: (2020)

T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities
por: Casciano, Fabio, et al.
Publicado: (2018)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials
por: Mosca, Megan, et al.
Publicado: (2021)

Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis
por: Ding, Huanxin, et al.
Publicado: (2022)

Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study
por: Huang, Yu-Huei, et al.
Publicado: (2022)

Liangxue Jiedu Formula Improves Psoriasis and Dyslipidemia Comorbidity via PI3K/Akt/mTOR Pathway
por: Xie, Xinran, et al.
Publicado: (2021)

Psoriasis and comorbidities: links and risks
por: Ni, Catherine, et al.
Publicado: (2014)

Comparison of Behavioral Risk Factors and Cardiometabolic Comorbidities of Psoriatic Arthritis and Psoriasis: A Case–Control Study in Chinese Patients
por: Wang, Qiaolin, et al.
Publicado: (2021)

Aging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis
por: Zhang, Xin-Xin, et al.
Publicado: (2021)

Caspase-4 and -5 Biology in the Pathogenesis of Inflammatory Bowel Disease
por: Smith, Aoife P., et al.
Publicado: (2022)

Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules
por: He, Huan, et al.
Publicado: (2021)

Psoriasis: Comorbidities
por: Yamazaki, Fumikazu
Publicado: (2021)

Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment
por: Hu, Stephen Chu-Sung, et al.
Publicado: (2017)

Body Composition, Cardiometabolic Risk Factors and Comorbidities in Psoriasis and the Effect of HLA-C*06:02 Status: The HUNT Study, Norway
por: SOLVIN, Åshild Ø., et al.
Publicado: (2023)

Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials
por: Di Lernia, Vito, et al.
Publicado: (2022)

Pathogenesis and therapy of radiation enteritis with gut microbiota
por: Yang, Qilin, et al.
Publicado: (2023)

Evidence and Potential Mechanism of Action of Lithospermum erythrorhizon and Its Active Components for Psoriasis
por: Wang, Jiao, et al.
Publicado: (2022)

Discovering Novel Biomarkers Associated with the Pathogenesis of Psoriasis: Evidence from Bioinformatic Analysis
por: Yang, Yang, et al.
Publicado: (2022)

Current and promising therapies based on the pathogenesis of Graves’ ophthalmopathy
por: Zhang, Xin, et al.
Publicado: (2023)

Comorbidities and cardiovascular risk factors in patients with psoriasis
por: Baeta, Isabela Guimarães Ribeiro, et al.
Publicado: (2014)

Suicide risk and psychiatric comorbidity in patients with psoriasis
por: Pompili, Maurizio, et al.
Publicado: (2016)

Double trouble: psoriasis and cardiometabolic disorders
por: Nasrin, Goolam Mahyoodeen, et al.
Publicado: (2018)

Psoriasis: new comorbidities
por: Machado-Pinto, Jackson, et al.
Publicado: (2016)

Comorbidity in Men with Psoriasis
por: Salihbegovic, Eldina Malkic, et al.
Publicado: (2021)

BIOLOGICAL THERAPY OF PSORIASIS
por: Sivamani, Raja K, et al.
Publicado: (2010)

Precision Medicine in Alzheimer’s Disease: Investigating Comorbid Common Biological Substrates in the Rat Model of Amyloid Beta-Induced Toxicity
por: Morgese, Maria Grazia, et al.
Publicado: (2022)

Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy
por: Brożyna, Anna A., et al.
Publicado: (2022)

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms
por: Zhang, Shuo, et al.
Publicado: (2022)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ikr27bmatn6mj1gnuqqc3mhkr7